Study · DSIP■Weak / none
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.
This narrative review, published in the Journal of the American Academy of Orthopaedic Surgeons: Global Research & Reviews, surveys the mechanistic rationale for using therapeutic peptides — including BPC-157, TB-500, GHK-Cu, ipamorelin, CJC-1295, tesamorelin, sermorelin, semax, selank, and epitalon — in orthopaedic and musculoskeletal contexts. As a narrative review, it synthesises existing literature rather than generating new data; it carries no experimental controls, no patient cohort, and no statistical analysis of outcomes. Readers should weight it as an expert-curated overview, not as clinical evidence.
The review's own authors acknowledge the central limitation plainly: preclinical findings are promising, but clinical trials are currently lacking. That candid admission matters. For most peptides covered — BPC-157, TB-500, ipamorelin, and epitalon in particular — the mechanistic picture is built almost entirely on rodent and in-vitro models. Tesamorelin is the notable exception, carrying FDA approval for HIV-associated lipodystrophy on the basis of Phase III RCT data, though that evidence does not transfer to orthopaedic applications.
The review is useful as a...
Journal of the American Academy of Orthopaedic Surgeons. Global research & reviewsn=——Jan 1, 2026